Daylife Select
A point & click tool to create dynamic content portals. Learn More »
Editor's Picks
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
-
[Posted 12/04/2009] Endo, Novartis and FDA notified healthcare professionals of revisions to the Hepatic Effects section of the prescribing information to add new warnings and precautions about the potential for elevation in liver function tests during... Full Article at Drugs.com
-
A decade into the 21st century, the corporation as we have always known it is under siege from every quarter. Investors are disgruntled over losses. Trade unions are protesting lay offs. Non-government organisations are demanding more social awareness. Full Article at Economic Times
-
Swiss drug maker Novartis' vaccine and diagnostcs chief Andrin Oswald (L) and former World Health Organization (WHO) flu chief, now Novartis vaccine development specialist Klaus Stoehr (2nd L) wait with other pharmaceutical company representatives befor... View Photo »
-
With this new funding, FORMA will focus on advancing our internal target-based oncology programs and in parallel, we will continue to pursue non-dilutive collaborations to further build our integrated drug discovery platform ... Our collaborations with the Leukemia & Lymphoma Society, Novartis Institute...
SOURCE: Freshnews.com -
CHICAGO, Dec. 3 /PRNewswire-USNewswire/ -- Women's Health Foundation (WHF) proudly announces receiving the inaugural Power of Partnering Innovation Award, as part of the November 2009 Power of Partnering Conference sponsored by Novartis Pharmaceuticals... Full Article at PR Newswire
-
Now that eyecare company Alcon has seen its shares recover--rising almost 6 percent just yesterday--Novartis is more likely to buy that majority stake from Nestle. Full Article at FiercePharma
-
WALTHAM, Mass. , Dec. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2... Full Article at Freshnews.com
-
Swiss drug maker Novartis' vaccine and diagnostcs chief Andrin Oswald (L) and former World Health Organization (WHO) flu chief, now Novartis vaccine development head Klaus Stoehr wait before meeting with United Nations Secretary-General Ban Ki-moon and... View Photo »
-
Assuming licensure by the FDA and other regulatory agencies, HGS believes ZALBIN could become an important treatment for chronic hepatitis C. Novartis targets submission of marketing authorization applications under the brand name JOULFERON® in the rest of the world later this quarter, beginning with Eu...
SOURCE: News-Medical.net -
-
TEL AVIV (MarketWatch) -- Among the shares expected to see active trading in Thursday's session are those of the retailers as well as Bank of America, Comcast, GE, ICO, Siemens, Targacept, Vivendi and Toll Brothers. Aeropostale Inc. Full Article at MarketWatch
-
Research and Markets: This Essential Report on the Pharmaceutical Market in Switzerland is Now Available
Street InsiderDecember 3, 2009 6:18 AM EST -- Size -- Market Structure -- Reimbursed Drug Market -- Generics Sector -- OKP Generic Market Data, 2006 -- Generic Outlook -- OTC Sector -- Projections & Outlook -- Imports -- Parallel... Full Article at Street Insider
About Novartis
Wikipedia
There are no results for this module. Edit this module to change the search term used to query Wikipedia
Related Photos
prev
next
-
Getty Images
Swiss pharmaceuticals giant Novartis headquarter is pictured on January 28, 2009 in Basel. The Swiss pharmaceutical group Novartis announced today a net profit increased significantly from 25% to 8163 billion dollars (6.2 billion euros) for 2008 and expects another year of "record".
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis headquarter is pictured on January 28, 2009 in Basel. The Swiss pharmaceutical group Novartis announced today a net profit increased significantly from 25% to 8163 billion dollars (6.2 billion euros) for 2008 and expects another year of "record".
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis CEO and President Daniel Vasella (R) discusses with the COO Joerg Reinhardt (L) during the annual media conference 28 January 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis CEO and President Daniel Vasella gestures during the annual media conference on January 28, 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis CEO and President Daniel Vasella gestures during the annual media conference on January 28, 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis CFO Raymund Breu speaks during the annual media conference on January 28, 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis CEO and President Daniel Vasella gestures during the annual media conference on January 28, 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis CFO Raymund Breu gestures during the annual media conference on January 28, 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis CFO Raymund Breu speaks during the annual media conference on January 28, 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis chairman and chief executive Daniel Vasella speaks during the annual media conference on January 28, 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis chairman and chief executive of Daniel Vasella speaks during the annual media conference on January 28, 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis chairman and chief executive of Daniel Vasella speaks during the annual media conference 28 January 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis chairman and chief executive of Daniel Vasella speaks during the annual media conference 28 January 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis chairman and chief executive of Daniel Vasella speaks during the annual media conference 28 January 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis chairman and chief executive of Daniel Vasella speaks during the annual media conference 28 January 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis chairman and chief executive of Daniel Vasella smiles during the annual media conference 28 January 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis chairman and chief executive of Daniel Vasella gestures during the annual media conference 28 January 2009 in Basel.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis CFO Raymond Breu smiles during the annual media conference on January 28, 2009 in Basel.
View Photo » -
Reuters Pictures
Dr. Andrin Oswald, CEO of Novartis Vaccines and Diagnostics, talks with the media at the new Novartis facility in Holly Springs, North Carolina, November 24, 2009.
View Photo » -
Reuters Pictures
U.S. Secretary of Health and Human Services Kathleen Sebelius (L-R), HHS Assistant Secretary for Preparedness and Response Dr. Nicole Lurie, Novartis CEO and Chairman Daniel Vasella, North Carolina Governor Bev Perdue and North Carolina Commerce Secretary Keith Crisco tour the new Novar...
View Photo » -
Reuters Pictures
Jamie Iudica, director of engineering at Novartis, describes the "infectious production harvest" process during a tour of the new Novartis flu vaccine production facility in Holly Springs, North Carolina, November 24, 2009.
View Photo » -
Reuters Pictures
Matt Stober (R), global head of Technical Operations for Novartis Vaccines and Diagnostics, and Russell Thirsk of Novartis describe the flu vaccine manufacturing process to the media at the new Novartis facility in Holly Springs, North Carolina, November 24, 2009.
View Photo » -
Reuters Pictures
A Novartis employee works in the area where MF-59, a distinguishing immune response booster used by Novartis in Europe, is added to vaccines at the Novartis flu vaccine facility in Holly Springs, North Carolina, November 24, 2009.
View Photo » -
Reuters Pictures
A bio-reactor is seen located in the area where cells will be infected with the flu virus in the process of manufacturing vaccines at the Novartis facility in Holly Springs, North Carolina, November 24, 2009.
View Photo » -
Reuters Pictures
Dr. Andrin Oswald, chief executive of Novartis Vaccines and Diagnostics, speaks with the media at the new Novartis facility in Holly Springs, North Carolina, November 24, 2009.
View Photo »
Getty Images
Swiss pharmaceuticals giant Novartis headquarter is pictured on January 28, 2009 in Basel. The Swiss pharmaceutical group Novartis announced today a net profit increased significantly from 25% to 8163 billion dollars (6.2 billion euros) for 2008 and expects another year of "record".
View Photo »Related Topics
Related Videos
Related Quotes
- Previous
- Next
- 1/12
-
The potential of GPCRs as targets for drug discovery is well recognized, but it has always been a challenge to gain structural information on GPCRs ... We believe that the power of Heptares' technology to resolve GPCR structures and their expertise in small molecule chemistry will lead to rapid progress...
SOURCE: Biospace -
This is an excellent early deal for Heptares, endorsing our StaR technology and further strengthening our financial position ... The deal with the Novartis Option Fund demonstrates confidence that our approach can unlock the potential of GCPR targets and forms a solid foundation for other partnerships w...
SOURCE: Biospace -
Preparations for the pandemic have already helped more than double worldwide vaccine manufacturing capacity to 900 million doses from 400 million, the scientists from Novartis AG, the U.S. National Institutes of Health, Erasmus University and the World Health Organization said in the article
SOURCE: Medical News Today -
As the daughter of a breast cancer survivor, I felt it was important to work with Novartis Oncology on this initiative and lend my voice to promote awareness of breast cancer and the importance of early detection
SOURCE: EURweb -
The delivery disparity raises the specter of discriminatory distribution -- serious questions about whether Novartis may be purposefully filling other flu vaccine contracts at higher levels
-
From a regulatory perspective, the FDA has made Novartis jump through significant hoops already in its phase-three program, which implies that when the development program is finished most of the safety issues will have been well studied
SOURCE: Wall Street Journal -
Novartis has already started first deliveries of pandemic vaccines under quarantine to governments in Europe, despite the initially low yields with the current production seed strain provided by the World Health Organisation (WHO). A new seed strain could provide higher volumes
SOURCE: New Kerala -
Only three months after the declaration of the pandemic by the WHO, Novartis was able to ship the first batches of our pandemic vaccine under quarantine to governments in Europe pending EU approval
SOURCE: New Kerala -
These four senior executives have helped Portola achieve success to date with our diverse proprietary pipeline and global development and commercialization agreements with Novartis for elinogrel and Merck & Co., Inc. for betrixaban
SOURCE: PR Newswire -
Four international vaccine manufacturers have shown interest — GSK, Novartis, Baxter and recently, Sanofi Aventis — in doing clinical trials called ‘bridge trails’ in India once we make a commitment to purchase a minimum amount
SOURCE: Hindustan Times -
GSK does not have a generic arm like Novartis and Pfizer. So, if the company feels the need to have one, it might look at DRL. But it just signed a long-term marketing agreement, so it may prefer to pick up a small stake, rather than going for a full-blown acquisition.
SOURCE: Business Week -
We reckon, however, that Novartis will need to gain full control, if it wants to start extracting synergies by combining business units
SOURCE: CNBC
– Related Conversations
There are no results for this module. Edit the module to change the search term used to query Twitter.